Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03492697 · ClinicalTrials.gov registry record · Phase 1
A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961
A Phase 1 study of Healthy Subjects, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03492697: Completed Phase 1 study of Healthy Subjects, sponsored by Pfizer.
NCT03492697 is a Phase 1 study of Healthy Subjects that has completed, run by Pfizer. The registered enrollment target is 12 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03492697, a Phase 1 study of Healthy Subjects, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This open label study will evaluate the pharmacokinetics (PK) following single oral doses of different formulations of PF-06882961, including controlled release (CR) tablets at 2 release rates (long and short duration), an immediate release (IR) oral solution, and IR tablets, in healthy adult subjects.
Conditions Studied
Interventions
- DRUG PF-06882961 Immediate Release Tablet
- DRUG PF-06882961 Controlled Release Tablet (long)
- DRUG PF-06882961 Controlled Release Tablet (short)
- DRUG PF-06882961 Immediate Release Solution
Study Locations (1)
Connecticut
- Pfizer New Haven Clinical Research Unit - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-04-30 |
| Est. Completion | 2018-07-18 |
| Phase | Phase 1 |
What the finished NCT03492697 record still lists
NCT03492697 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 4 interventions - of which PF-06882961 Immediate Release Tablet is the first listed.
NCT03492697 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03492697 about?
NCT03492697 is a clinical study titled "A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961". This open label study will evaluate the pharmacokinetics (PK) following single oral doses of different formulations of PF-06882961, including controlled release (CR) tablets at 2 release rates (long and short duration), an immediate release (IR) oral solution, and IR tablets, in healthy adult subjec...
What is the current status of trial NCT03492697?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-04-30. Estimated completion is 2018-07-18.
What conditions does trial NCT03492697 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT03492697?
The interventions under investigation include: PF-06882961 Immediate Release Tablet (DRUG), PF-06882961 Controlled Release Tablet (long) (DRUG), PF-06882961 Controlled Release Tablet (short) (DRUG), PF-06882961 Immediate Release Solution (DRUG).
Who is sponsoring clinical trial NCT03492697?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03492697 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03492697's enrollment target sits among peer trials
12 62nd of 69 higher than 6 of 69 other Healthy Subjects trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI